On August 1, 2023, Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, announced the closing of its underwritten public offering of 14,375,000 shares of its common stock at a price of $4.80 per share. The shares of common stock issued and sold in the public offering at the closing include 1,875,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock in the public offering were sold by Inozyme.

BofA Securities, TD Cowen and Piper Sandler acted as joint book-running managers for the offering. Wedbush PacGrow and Needham & Company acted as co-managers for the offering.

The WilmerHale team advising Inozyme in its public offering was led by Brian Johnson and Caroline Dotolo, and included Andrea Sorrentino, Will Hall and Helen Park.